As to clinical application, several phase I/II clinical trials are undergoing, including CTX120 in relapsed or refractory multiple myeloma (Clinicaltrials.gov, NCT04244656), anti‐mesothelin CAR‐T cells modified by CRISPR/Cas9 in multiple solid tumors (Clinicaltrials.gov, NCT03545815), CTX110 in B‐cell malignancies (Clinicaltrials.gov, NCT04035434), CRISPR/Cas9 gene‐editing CAR‐T cells targeting CD19 (UCART019) in CD19+ leukemia and lymphoma (Clinicaltrials.gov, NCT03166878). The gene discussed is MSLN; the disease is plasma cell myeloma.